Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
5.56
-0.13 (-2.28%)
At close: Feb 12, 2026, 4:00 PM EST
5.56
0.00 (0.00%)
After-hours: Feb 12, 2026, 4:10 PM EST
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 71 employees as of December 31, 2024. The number of employees decreased by 29 or -29.00% compared to the previous year.
Employees
71
Change (1Y)
-29
Growth (1Y)
-29.00%
Revenue / Employee
$434,211
Profits / Employee
-$366,394
Market Cap
88.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 71 | -29 | -29.00% |
| Dec 31, 2023 | 100 | 78 | 354.55% |
| Dec 31, 2022 | 22 | -16 | -42.11% |
| Dec 31, 2021 | 38 | 9 | 31.03% |
| Dec 31, 2020 | 29 | 12 | 70.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Artiva Biotherapeutics | 106 |
| Seres Therapeutics | 103 |
| Immunic | 90 |
| aTyr Pharma | 65 |
| Biomea Fusion | 42 |
| eXoZymes | 31 |
| Oncolytics Biotech | 28 |
VRCA News
- 11 hours ago - Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer - GlobeNewsWire
- 3 days ago - Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical - GlobeNewsWire
- 5 weeks ago - Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway - GlobeNewsWire
- 3 months ago - Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 3 months ago - Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire